Charles R. Crawley

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Journal: Bone marrow transplantation

Published: March 27, 2026

Splenic radiotherapy before allogeneic transplantation for myelofibrosis.

Splenic radiotherapy before allogeneic transplantation for myelofibrosis.

Journal: British journal of haematology

Published: February 21, 2026

Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party.

Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party.

Journal: Bone marrow transplantation

Published: October 03, 2025

Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.

Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.

Journal: HLA

Published: July 09, 2025

Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.

Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.

Journal: Bone marrow transplantation

Published: June 11, 2025

Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.

Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.

Journal: Bone marrow transplantation

Published: March 02, 2025

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT.

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT.

Journal: Bone marrow transplantation

Published: February 06, 2025

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies.

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 21, 2024

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.

Journal: Blood

Published: February 20, 2024

Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.

Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.

Journal: Bone marrow transplantation

Published: January 09, 2024

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Journal: British journal of haematology

Published: October 15, 2023

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Journal: Blood

Published: June 20, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026